

International Atomic Energy Agency Department of Technical Cooperation And Nuclear Medicine and Diagnostic Imaging Section Division of Human Health

WS-RAS6091-EVT1901109 End-of-mission Report

IAEA Regional Workshop on Nuclear Neurology SPECT and PET applications in dementia, movement disorder, and epilepsy

July 29 - Aug 2, 2019

National Center of Neurology and Psychiatry, Tokyo, Japan

Local Course Director

MATSUDA, Hiroshi
Integrative Brain Imaging Center (IBIC)
National Center of Neurology and Psychiatry (NCNP)
4-1-1, Ogawahigashi, Kodaira, Tokyo
187-8551 JAPAN
Tel: 81423412711

Tel: 81423412711 Fax: 81423462229

E-mail: matsudah@ncnp.go.jp

Participants

Md Murshed ALI Bangladesh

Ashoke PAUL Bangladesh

Li WANG China

Esmaeil GHAREH PAPAGH Iran

Aza Ismail Abdi ABDI Iraq

Mohamed Sadoon Mohson AL-SHAMMAA Iraq

Rafid Riyadh AL-TUMA Iraq

Konstantin GOUREVICH Israel

Viengkham LEUANGVANXAY Lao P.D.R.

Sackmone SYCHALEUN Lao P.D.R.

Khin Pa Pa MYO

Myanmar

Ms Thiri Kyi PHYU

Myanmar

Shaheen IQBAL

Pakistan

Omair SAJJAD

Pakistan

Juanito Jr OLPINDO

Philippines

Arlene ORTIZ

Philippines

Mohammed ALHARBI

Saudi Arabia

Wanying XIE

Singapore

Tawika KAEWCHUR

Thailand

UAE

Tanyaluck THIENTUNYAKIT Thailand

Batool ESSA GHULAM ABDULLA ALBALOOSHI

Quan NGUYEN

Viet Nam

Nguyen PHUONG

Viet Nam

Sharaf SHAREEF

Yemen

PROGRAM

Monday, 29 July 2019			
Multimedia hall (Library and Conference Center 1F, NCNP)			
09:30-9:50	Registration		
9:50-10:30	Opening remarks Self-Introduction Pre-Course Evaluation	Prof. Hidehiro Mizusawa (President, NCNP Prof. Jun Hatazawa (President, Japanese Society of Nuclear Medicine, Asia Oceania Foundation of Nuclear Medicine and Biology) Prof. Hiroshi Matsuda (Course Director)	
SESS	SION 1 (Radiopharmaceu	tical and Image	Analysis)
CHAIR: Prof. Hiroshi M National Center	atsuda of Neurology and Psychiatry, Jap	an	
10:30-11:00	Overview of PET radiopharmaceutical		Dr. Harumasa Takano (IBIC, NCNP)
	 ILO: 1. Recognize the significance of radiopharmaceuticals used in PET brain imaging. 2. Integrate the concepts of radiopharmaceuticals in brain imaging within the context of best practices of the nuclear technology on the brain imaging 		(IBIC, IVCIVI)
11:00-12:00	Overview of SPECT radiopharmaceutical ILO: 1. Recognize the significance of radiopharmaceuticals used in SPECT/CT brain imaging. 2. Integrate the concepts of radiopharmaceuticals in brain imaging within the context of best practices of the nuclear technology on the brain imaging		Prof. Hiroshi Matsuda (IBIC,NCNP)
12:00-13:30	Lunch Break		
13:30-14:20	Statistical Image Analysis ILO: Review and understand basic conc parametric analysis used in SPECT with CT or MR for Neurological In Medicine techniques	and PET combined	Prof. Hiroshi Matsuda (IBIC,NCNP)

14:20-15:10	Dementia; SPECT diagnosis	Prof. Hiroshi
		Matsuda
	ILO:	(IBIC,NCNP)
	1. Understand the pathophysiology of Alzheimer's	
	disease.	
	2. Discuss the risk factors of Alzheimer's disease.	
	3. Discuss the role of SPECT nuclear medicine imaging	
	in Alzheimer's disease	
15:10-16:00	SPECT measures	Prof. Hiroshi
		Matsuda
	1. Understand the significance of SPECT	(IBIC,NCNP)
	measurements/ quantification factors used in PET brain	
	imaging.	
	2. Integrate the concepts of radiopharmaceuticals in	
	brain imaging within the context of best practices of the	
	nuclear technology on the brain imaging	
End of SESSION 1		
18:30- Welcome Reception		
(Venue: Shinjuku Prince Hotel 25F, Restaurant FUGA)		

IAEA

Tuesday, 30 July 2019

Multimedia hall (Library and Conference Center 1F, NCNP)

SESSION 2 (Epilepsy)


CHAIR:

Prof. Hiroshi Matsuda

National Center of Neurology and Psychiatry, Japan

09:00-10:00	Clinical diagnosis, Medical Treatment	Dr. Eiji Nakagawa
		(Department of Child
	ILO:	Neurology, NCNP)
	1. Understand the pathophysiology of seizures	
	2. Discuss the risk factors	
	3. Discuss the role of nuclear medicine imaging in	
	seizures	
10:00-11:00	Epileptic Surgery	Dr. Masaki Iwasaki
		(Department of
	ILO:	Neurosurgery,
	1. Understand the importance of surgical management in	NCNP)
	seizures in the context of nuclear imaging	
11:00-12:00	MRI diagnosis of epilepsy	Dr. Noriko Sato
		(Department of
	ILO:	Radiology, NCNP)
	1. Describe appropriate ways of report writing in	
	neurological cases with MR interpretation	
	2. Discuss the role of Brain Imaging using actual cases	
	for image interpretation and its relevance in clinical	
	practice	
12:00-13:30	Lunch Break	
		I
13:30-15:00	FDG PET for detection of epileptic focus	Dr. Emiko Morimoto
	W 0	(Department of
	ILO:	Radiology, NCNP)
	1. Understand the pathophysiology of seizures	
	2. Discuss the risk factors	
	3. Discuss the role of nuclear medicine imaging in	
15.00.16.00	seizures	D ** 1 · **
15:00-16:00	SISCOM for detection of epileptic focus	Dr. Yukio Kimura
	и о	(Department of
	ILO:	Radiology, NCNP)
	1. Understand the pathophysiology of seizures	
	2. Discuss the risk factors	
	3. Discuss the role of SISCOM in seizures	

End of SESSION 2



Wednesday, 31 July 2019

Multimedia hall (Library and Conference Center 1F, NCNP)

SESSION 3 (Dementia)

CHAIR:

Prof. Hiroshi Matsuda

National Center of Neurology and Psychiatry, Japan			
09:00-10:00	Clinical Diagnosis of Alzheimer's disease ILO:	Dr. Yuma Yokoi (PMDA, Department of Psychiatry, NCNP)	
	1. Understand the pathophysiology of Alzheimer's	of i sycinatry, incini	
	disease.		
	2. Discuss the risk factors of Alzheimer's disease.		
	3. Discuss the role of nuclear medicine imaging in		
	Alzheimer's disease		
10:00-11:00	Clinical Diagnosis of Dementia with Lewy Bodies	Dr. Tadashi	
	·	Tsukamoto	
	ILO:	(Department of	
	1. Understand the pathophysiology of Dementia with	Neurology, NCNP)	
	Lewy Bodies.		
	2. Discuss the risk factors of Dementia with Lewy		
	Bodies.		
	3. Discuss the role of nuclear medicine imaging in		
	Dementia with Lewy Bodies		
11:00-12:00	MRI diagnosis of Dementia	Dr. Noriko Sato	
	W 0	(Department of	
	ILO:	Radiology, NCNP)	
	1. Discuss the role of nuclear medicine imaging and		
12:00-13:30	MRI in Dementia Lunch Break		
12:00-13:30	Lunch Break		
13:30-14:30	PET/MRI Molecular imaging	Prof. Hidehiko	
		Okazawa	
	ILO:	(Biomedical Imaging	
	1. Discuss the role of PET/MRI nuclear medicine	Research Center,	
	imaging in Alzheimer's disease	Fukui University)	
14:30-15:30	Molecular Imaging	Dr. Yoko Shigemoto	
	W 0	(Department of	
	ILO:	Radiology, NCNP)	
	1. Understand the pathophysiology of Alzheimer's		
	disease.		
	2. Discuss the risk factors of Alzheimer's disease.		
	3. Discuss the role of molecular imaging in Alzheimer's		
	disease		

15:30-16:30	PET measures	Dr. Kyoji Okita
		(IBIC, NCNP)
	ILO:	
	1. Understand the significance of PET measurements/	
	quantification factors used in PET brain imaging.	
	2. Integrate the concepts of radiopharmaceuticals in	
	brain imaging within the context of best practices of the	
	nuclear technology on the brain imaging	

End of session 3

17:00- Excursion and Dinner

(Venue: Tokyo Tower and Japanese Restaurant near Tokyo Tower)



Thursday, 1 August 2019

Multimedia hall (Library and Conference Center 1F, NCNP)

SESSION 4 (Movement Disorder)

CHAIR:

Prof. Hiroshi Matsuda

National Center of Neurology and Psychiatry, Japan

	National Center of Neurology and Psychiatry, Japan			
09:00-10:00	Clinical diagnosis, Medical Treatment	Dr. Noriko Nishikawa		
		(Department of		
	ILO:	Neurology, NCNP)		
	1. Understand the pathophysiology of Movement			
	disorders.			
	2. Discuss the utilization of nuclear medicine imaging			
	modalities in the evaluation of movement disorders			
10:00-11:00	Deep Brain Stimulation	Dr. Yuiko Kimura		
	•	(Department of		
	ILO:	Neurosurgery, NCNP)		
	1. Discuss the utilization of Deep Brain Simulation in			
	the evaluation of movement disorders			
11:00-12:00	MRI diagnosis of movement disorders	Dr. Yukio Kimura		
		(Department of		
	ILO:	Radiology, NCNP)		
	1. Discuss the utilization of MRI in the evaluation of			
	movement disorders			
12:00-13:30	Lunch Break			
	Blood flow and Metabolism	Prof. Hiroshi Matsuda		
		(IBIC,NCNP)		
	ILO:			
	1. Review the significance of Blood flow and			
	metabolism in the management of movement disorders			
	Role of MIBG	Prof. Hiroshi Matsuda		
	Note of MIDO			
		(IBIC,NCNP)		
	ILO:			
	ILO: 1. Review the significance of MIBG in the			
	ILO: 1. Review the significance of MIBG in the management of movement disorders	(IBIC,NCNP)		
	ILO: 1. Review the significance of MIBG in the			
	ILO: 1. Review the significance of MIBG in the management of movement disorders	(IBIC,NCNP) Prof. Hiroshi Matsuda		
	ILO: 1. Review the significance of MIBG in the management of movement disorders Role of DaT SPECT ILO:	(IBIC,NCNP) Prof. Hiroshi Matsuda		
	ILO: 1. Review the significance of MIBG in the management of movement disorders Role of DaT SPECT	(IBIC,NCNP) Prof. Hiroshi Matsuda		

END OF SESSION 4

Friday, 2 August 2019

Multimedia hall (Library and Conference Center 1F, NCNP)

SESSION 5 (Neuropathology and Radiochemistry)

CHAIR:


Prof. Hiroshi Matsuda

National Center of Neurology and Psychiatry, Japan

09:00-10:00	Neuropathology of neurodegenerative diseases	Dr. Yuko Saito	
		(Department of	
	ILO:	Neuropathology,	
	1. Understand the pathophysiology of neurodegenerative disorders	NCNP)	
	2. Discuss the utilization of nuclear medicine imaging		
	modalities in the evaluation of neurodegenerative		
	disorders		
10:00-11:00	Radiochemistry and Pharmacy	Dr. Koichi Kato (IBIC, NCNP)	
	ILO:		
	 Recognize the significance of radiopharmaceuticals used in neurodegenrative disorder imaging. Integrate the concepts of radiopharmaceuticals in 		
	brain imaging within the context of best practices of the nuclear technology on the brain imaging"		
End of Session 5			
11:00-12:00	Closing Remarks	Prof. Hiroshi	
	Post course evaluation	Matsuda	
		(IBIC.NCNP)	

Average total scores in Pre- and Post-course evaluation

Pre- 42.8 Post- 60.8





Pictures



Pariticipants and NCNP staffs with Prof. Jun Hatazawa (President of Japanese Society of Nuclear Medicine)



Lecture



Reception dinner party



Excursion to Tokyo tower

This workshop is accredited by the UEMS- EACCME (European Union of Medical Specialists - European Accreditation Council for Continuing Medical Education) with 24 European CME credits.

